3Harvey PD,Keefe RSE.Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment[J].Am J Psychiatry,2001,158:176-184.
2Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia[ J]. Clinical Therapeutics ,2002,24:21-37.
3Harvey PD, Bowie CR. Ziprasidone : efficacy, tolerabicity, andemerging data on wide ranging effectiveness[ J ]. Expert opin Pharma Cother,2005,6:337-339.
4Emsley R, Osthuizen P. The new and evolving pharrn a cotherapy of schizophrenia[J]. Psychial Clin North Am,2003,26:141-163.
5Laloude P. Evaluating antipsychotic medications : predictors of clinical effectiveness[ J]. Can J Psychiat ,2003 ,48 :4-12.
6Stimmel GL, Gutierrez MA, Lee V. Ziprasidone : an atypical antipsychotic drug for the treatment of schizophrenia [ J ]. Clinical Therapeutics ,2002,24:21-37.
7SCHATZBERG AF, NEMEROFF CB. Textbook of psychophar- macology[M]. 3rd Ed. Washington, DC: The American Psy- chiatric Publishing Inc, 2004 : 885-912.
8SADOCK B J, SADOCK VA. Kaplan & Sadock's comprehensive textbook of psychiatry[M]. 8th Ed. Philadelphia: Lippincott Williams & Wilkins Inc, 2005 : 1329-1476.
9JANICAK PG, DAVIS JM, PRESKORN SH, et al. Principles & practice of psychopharmacotherapy[M]. 3rd Ed. Philadelphia: Lippincott Williams & Wilkins Inc, 2001, 73-141.
10FISCHMAN AJ, BONAB AA, BABICH JW, et al. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone[J]. J Pharmacol Exp Ther, 1996, 279(2) : 939-947.
